Cholecystokinin Receptor Antagonist Improves Efficacy of Chemotherapy in Murine Models of Pancreatic Cancer by Altering the Tumor Microenvironment

SIMPLE SUMMARY: Our research team has identified the cholecystokinin-B receptor (or CCK-BR) as a novel target for treatment of pancreatic cancer. CCK-BRs are over-expressed in pancreatic cancer and activation stimulates growth in cell culture and in animal models. CCK-BRs are also expressed on pancr...

Descripción completa

Detalles Bibliográficos
Autores principales: Malchiodi, Zoe X., Cao, Hong, Gay, Martha D., Safronenka, Anita, Bansal, Sunil, Tucker, Robin D., Weinberg, Benjamin A., Cheema, Amrita, Shivapurkar, Narayan, Smith, Jill P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8508339/
https://www.ncbi.nlm.nih.gov/pubmed/34638432
http://dx.doi.org/10.3390/cancers13194949

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8508339/
https://www.ncbi.nlm.nih.gov/pubmed/34638432
http://dx.doi.org/10.3390/cancers13194949

Ejemplares similares